SCHEMBL15065809

SCHEMBL15065809

O=Cc1ccc(N2CCN(C(=O)O)CC2)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 3/20 0.64
PIK3CD O00329 2/20 0.64
PIK3CA P42336 2/20 0.64
PIK3CB P42338 2/20 0.64
PIK3CG P48736 2/20 0.64
ALDH1A1 P00352 3/20 0.42
ME2 P23368 1/20 0.39
ME1 P48163 1/20 0.39
ME3 Q16798 1/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
TYR P14679 2/20 0.38
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13278385 0.84 PIK3CD (0.44) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL7039585 0.82 PIK3CD (0.73) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18493255 0.82 PRKDC (0.73) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL11262976 0.81 PIK3CD (0.68) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL28868212 0.81 MAPT (0.63) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL11297084 0.81 PIK3CD (0.71) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
Hydrochloric Acid SCHEMBL25231967 0.80 PIK3CD (0.66) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL15066686 0.80 PIK3CD (0.54) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL27985655 0.78 PRKDC (0.40) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL29458331 0.78 PRKDC (1.00) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024064026-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-03-28 WO disclosed
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 PRKDC 3476/4885PIK3CD 3763/4885PIK3CA 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.